Active Pharmaceutical Ingredients (API), also known as bulk pharmaceuticals or drug substances, are the primary biologically active components in medications that produce the intended therapeutic effect. These substances are responsible for the pharmacological activity of the drug product.
Here’s a clear breakdown of the leading companies in the API industry based on their market capitalization (as of November 2024):
- Eli Lilly: $709.84 Billion
- AbbVie: $320.09 Billion
- Merck: $257.06 Billion
- Novartis: $207.54 Billion
- AstraZeneca: $205.75 Billion
- Pfizer: $146.03 Billion
- Sanofi: $121.89 Billion
- GlaxoSmithKline (GSK): $69.40 Billion
- Teva Pharmaceutical Industries: $18.79 Billion
- Viatris: $15.61 Billion
The global active pharmaceutical ingredient industry, valued at US$158.1 billion in 2023, is forecasted to grow at a robust CAGR of 7.8%, reaching US163.5 billion in 2024 and an impressive US$238.3 billion by 2029.
Read also:
Resource Person: Mohamed Shehab
